Sharp Therapeutics Corp.
SHRX.V
TSX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 0.00% | -121.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.00% | -65.99% | |||
| Operating Income | 0.00% | 65.99% | |||
| Income Before Tax | 0.00% | 93.76% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 0.00% | 93.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.00% | 93.76% | |||
| EBIT | 0.00% | 65.99% | |||
| EBITDA | 0.00% | 66.20% | |||
| EPS Basic | 0.00% | 99.95% | |||
| Normalized Basic EPS | 0.00% | 99.83% | |||
| EPS Diluted | 0.00% | 99.95% | |||
| Normalized Diluted EPS | 0.00% | 99.83% | |||
| Average Basic Shares Outstanding | 0.00% | 12,719.24% | |||
| Average Diluted Shares Outstanding | 0.00% | 12,719.24% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||